Article Per Year (5 Year)
p-Index From 2020 - 2025
2.723
P-Index
This Author published in this journals
All Journal International Journal of Integrated Health Sciences Majalah Kedokteran Bandung Althea Medical Journal Indonesian Journal of Cancer Majalah Kedokteran Sriwijaya Indonesian Journal of Rheumatology Majalah Patologi Indonesia Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML) Indonesian Journal of Cancer
Amaylia Oehadian
Division Of Hematology And Medical Oncology, Department Of Internal Medicine, Faculty Of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 25 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 25 Documents
Search

 1   2   3 
Prognostic Nutritional Index and Systemic Immune-inflammation Index: Possible New Parameters for COVID-19 Severity Suyoso, Suyoso; Oehadian, Amaylia; Khotijah, Alfreda Amelia; Marthoenis, Marthoenis
Althea Medical Journal Vol 10, No 3 (2023)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/amj.v10n3.3061

Abstract

Background: The prognostic nutritional index (PNI) parameter has been widely used in estimating the severity of COVID-19. In contrast, investigating the role of the systemic immune-inflammation index (SII) in determining the COVID-19 severity is prospective. This study aimed to investigate the potential of PNI and SII parameters to distinguish the severity of symptoms of COVID-19.Methods: A retrospective observational study was conducted among 209 hospitalized patients with COVID-19. Data were collected from August 2021 to February 2022 in Indonesia’s general COVID-19 referral hospital. Demographic and laboratory data, including PNI and SII, were analyzed and compared between the severe and non-severe symptoms of COVID-19 patients. The statistical analysis of the receiver operating characteristic curve (ROC) and area under curve (AUC) was conducted to predict the potential of these parameters in distinguishing the COVID-19 severity. Results: More than half of this study’s patients (54.55%) were non-severe COVID-19. The SII values in patients with severe symptoms were significantly higher than in those with non-severe symptoms (2,445.24 vs. 1,423.28, p=0.005). In contrast, the PNI value in patients with severe COVID-19 symptoms was significantly lower than those with non-severe symptoms (38.04 vs. 33.93, p<0.001). The area under the curve (AUC) value of PNI was 0.694, meanwhile the SII was 0.635. The optimum cut-off for the PNI was <35.407, whereas the SII was >2,212.787. PNI and SII were the potential new diagnostic parameters for COVID-19 severity.Conclusion: PNI and SII parameters can potentially distinguish the severity of symptoms of COVID-19.
Difference of Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio in Patients with Non-Hodgkin and Hodgkin Lymphoma Jones, Frenky; Mersiana, Lusi; Oehadian, Amaylia; Marthoenis, Marthoenis
Althea Medical Journal Vol 11, No 4 (2024)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/amj.v11n4.3335

Abstract

Background: Malignancy and inflammation are strongly connected. The inflammatory processes play a significant part in the development of lymphoma. Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) can be used as potential biomarkers of inflammation in lymphoma. This study aimed to discover the differences between NLR, MLR, and PLR in patients diagnosed with non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). Methods: This study employed a retrospective design using data from the lymphoma registry at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia from 2020 to 2023. Sampling was carried out consecutively. Hematological data of patients with NHL and HL before chemotherapy were collected. The variance between the two groups was examined utilizing the Mann-Whitney U test.Results: In total, 122 data of patients were included, consisting of 75% NHL patients and 25% HL patients with a median age of 54 years (IQR 43–62). The overall NLR, MLR, and PLR tended to be lower in nHL than in HL patients although the differences were not statistically significant; with NLR 2.7 (0.7 – 12.2) vs. 3.2 (1.1 – 10.8)  p=0.287, MLR 0.36 (0.04 – 1.86) vs. 0.46 (0.09 – 1.78) p=0.150, and PLR was 160.6 (20.2 – 1533.3) vs. 211.2 (50.6–1156.3) p=0.189, for NHL and HL, respectively.Conclusion: The lower values of NLR, MLR, and PLR in NHL indicate lower systemic inflammatory status in NHL than HL patients. Further studies are needed to evaluate dynamic changes of these biomarkers during treatment.
Ifosfamide-Induced Encephalopathy in Relapsed Lymphoma: Report of Two Cases Takaryanto, Davin; Harti, Gusti Fungani; Oehadian, Amaylia
International Journal of Integrated Health Sciences Vol 12, No 2 (2024)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/ijihs.v12.n2.3558

Abstract

Objective: Ifosfamide is a chemotherapeutic drug available for various malignancy, including lymphoma. Ifosfamide has adverse effects including myelosuppression, nephrotoxicity, hemorrhagic cystitis, and neurotoxicity. Encephalopathy is a severe manifestation of neurotoxicity due to ifosfamide, with an incidence of 10–40%. This study aimed to report two cases of ifosfamide-induced encephalopathy.Case: This case studies reported two relapsed lymphoma patients with almost similar characteristics who received ifosfamide chemotherapy. The first case of 48-year-old woman with relapsed High-Grade B-cell lymphoma stage IIIBE while the second case of 38-year-old woman with relapsed non-hodgkin lymphoma. The first case showed a good outcome with improvement in consciousness 48 hours after stopping ifosfamide and thiamine, while the second case experienced tumor lysis syndrome, leading to the death of the patient.Conclusion: Mechanism of ifosfamide-induced encephalopathy remains unclear, with the hypothesis from the neurotoxic effects of the resultant metabolite chloracetyldehide. Radiology examination of the brain and electroencephalography is required to rule out other differential diagnoses. Early recognition of adverse effects, followed by immediate discontinuation of ifosfamide, administration of therapy, such as methylene blue and/or thiamine, and supportive treatment usually produced good outcomes.
Eribulin in Heavily Pre-Treated Metastatic Breast Cancer: A Case Series Kartikasari, Andini; Oehadian, Amaylia
International Journal of Integrated Health Sciences Vol 13, No 1 (2025)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/ijihs.v13n1.3908

Abstract

Background: Treatment options are limited for heavily pre-treated metastatic breast cancer patients, with Eribulin showing promise in improving survival outcomes.Objective: To evaluate Eribulin outcomes in patients with MBC. Metastatic or incurable diseases are observed in 4% to 10% of women despite advances in breast cancer treatment. To address this problem, EMBRACE, an important randomized phase III clinical trial was carried out by comparing eribulin to the treatment selected by physicians for individuals with previously treated locally recurrent or metastatic breast cancer (MBC). The results showed a significant and prolonged increase in median overall survival among patients treated with eribulin, compared to those who received the physician's selected treatment.Case Series: This study presents three patients who showed favorable outcomes after treatment with eribulin, despite multiple lines of previous therapy. Patient 1 was diagnosed with triple-negative breast cancer and initially achieved remission before experiencing a recurrence involving a chest lesion and enlarged lymph nodes. After two cycles of eribulin, the patient showed significant improvement. Patient 2 developed brain and liver metastases following the completion of hormonal therapy, prompting the initiation of eribulin as the next line of treatment. Patient 3 had disease progression despite undergoing multiple lines of hormonal and chemotherapy. Eribulin was administered and patient remained stable.Conclusion: Patients with MBC tend to have substantially favorable outcomes with eribulin chemotherapy even after extensive previous treatment.
Gambaran Klinikopatologi Limfoma Sel B Besar Difus Tidak Tertentu di Rumah Sakit Umum Pusat Dr. Hasan Sadikin Bandung Tahun 2018-2023 Afiati; Hernowo, Bethy S.; Aminah, Hermin; Oehadian, Amaylia
Majalah Patologi Indonesia Vol. 34 No. 3 (2025): MPI
Publisher : Perhimpunan Dokter Spesialis Patologi Anatomik Indonesia (PDSPA)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55816/mpi.v34i3.675

Abstract

Introduction Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), is the most common group of non-Hodgkin malignant lymphoma globally, representing 25%-40% of adult lymphoma cases. According to the cell of origin(COO), DLBCL NOS is classified into DLBCL germinal center B-cell like(GCB) and DLBCL non-germinal center B-cell like(non-GCB). Since the COO affects the prognosis of DLBCL NOS, this examination is important. Hans algorithm is the most frequently used to distinguish the GCB from non-GCB. This study aims to describe clinicopathological characteristics of DLBCL NOS at Dr. Hasan Sadikin General Hospital Bandung, 2018-2023. Methods The subjects of this retrospective descriptive study were DLBCL GCB and non-GCB patients based on Hans algorithm by IHC examination of CD10, BCL6, and MUM1 who received R-CHOP therapy at Dr. Hasan Sadikin General Hospital from 2018 to 2023. All data contained age, gender, B-symptoms, primary tumor location, stage, total International Prognostic Index (IPI) score, and immunochemotherapy status.  Results A total of 55 patients diagnosed with DLBCL NOS were collected in this study. 50 patients(90.9%) were classified as DLBCL non-GCB and 5 patients(9.1%) were classified as DLBCL GCB. The average age was 62 years, predominantly males(52.7%), extranodal disease(54.5%), no B symptoms(76.4%), and early stage(83.7%). 52 patients(94.6%) had a total IPI score of 0-1, 3 patients(5.4%) had a total IPI score of 2. 21 patients(38.2%) had a response, 13 patients(23.6%) had non-response, and 21 patients(38.2%) are still ongoing to R-CHOP therapy. Conclusion DLBCL NOS at Dr. Hasan Sadikin General Hospital from 2018-2023 mainly occurred in men with an average 62 years old and extranodal disease without B-symptoms. DLBCL non-GCB was predominant than GCB. Both DLBCL Non-GCB and GCB were mostly diagnosed at early stage, IPI low-risk group, and had response status to R-CHOP therapy similar to those are still ongoing to R-CHOP therapy.
Co-Authors A.A. Ketut Agung Cahyawan W Abdul Hadi Martakusumah Afiati Afiati Afiati Agnes Rengga Indrati Agung Firmansyah Sumantri Agung Firmansyah Sumantri Aminah, Hermin Andiyang R. Diredja Andri Reza Rahmadi Augusta Y. L. Arifin Bachti Alisjahbana Bethy S. Hernowo Camelia Khairun Nissa Dania Artriana Riswandi Delita Prihatni Doloksaribu, Rismauli Een Hendarsih Evan Susandi Fransisca Fransisca Fransisca Fransisca Gultom, Santi Christiani Guntur Darmawan Harti, Gusti Fungani Hery Aprijadi Husna, Rizka Iman Supandiman Indra Wijaya Ismiana Fatimah Modjaningrat Jeffery Malachi Candra Jones, Frenky Kartikasari, Andini Kevin Yonatan Budiman Khotijah, Alfreda Amelia Kiki Akhmad Rizki Laniyati Hamijoyo, Laniyati Lisda Amalia M. Fuad M. Marthoenis Martina Sung Mersiana, Lusi Modjaningrat, Ismiana Fatimah Mohammad Ghozali Mohammad Ghozali, Mohammad Muhammad Mufakkirul Islam Pandji Irani Fianza Putri Vidyaniati Rachmat Sumantri Rahmaniati Rahmaniati Rahmaniati, Rahmaniati Ria Bandiara Susi Susanah Suyoso Suyoso Takaryanto, Davin Tonggo Gerdina Panjaitan Trinugroho H Fadjari, Trinugroho H Trinugroho Heri Uun Sumardi, Uun Wenny Simamora Yeny Tanoyo Yussy Afriani Dewi